honglouwawa/iStock via Getty Images While Eli Lilly missed on both the top and bottom lines in its Q3 financial results, a look at its sales figures -- and especially sales growth -- would make many other pharmaceutical companies jealous. Driven by strong revenue growth.
Back to Health Page
